Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-25
2006-07-25
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S070000, C544S092000
Reexamination Certificate
active
07081457
ABSTRACT:
Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure:wherein R1and R2are selected from the group of H, optionally substituted C1to C6alkyl, alkenyl, alkynyl, or alkynyl groups C3to C8cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORAor NRBCORA; or R1and R2are fused to form an optionally substituted ring structure as defined herein; RAand RBare as defined herein; R3is H, OH, NH2, CORC, or optionally substituted C1to C6alkyl, C3to C6alkenyl, or alkynyl groups; RCis as defined herein; Q1is S, NR7, or CR8R9; R5is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring.
REFERENCES:
patent: 3526621 (1970-11-01), Bernardi et al.
patent: 3635941 (1972-01-01), Weaver et al.
patent: 3635964 (1972-01-01), Skorcz
patent: 3917592 (1975-11-01), Kobzina
patent: 4093730 (1978-06-01), Butti et al.
patent: 4440785 (1984-04-01), Walsh
patent: 4666913 (1987-05-01), Kubla et al.
patent: 4670566 (1987-06-01), Walsh
patent: 4721721 (1988-01-01), Kuhla et al.
patent: 4792561 (1988-12-01), Walker et al.
patent: 4822794 (1989-04-01), Spada et al.
patent: 4831027 (1989-05-01), Narr et al.
patent: 4853473 (1989-08-01), Fischer et al.
patent: 5007952 (1991-04-01), Kume et al.
patent: 5171851 (1992-12-01), Kim et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5447928 (1995-09-01), Williams et al.
patent: 5453516 (1995-09-01), Fischer et al.
patent: 5475020 (1995-12-01), Johnson et al.
patent: 5519021 (1996-05-01), Young et al.
patent: 5521166 (1996-05-01), Grubb
patent: 5681817 (1997-10-01), Hodgen et al.
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5733902 (1998-03-01), Schneider
patent: 5808139 (1998-09-01), Pathirana et al.
patent: 5874430 (1999-02-01), Christ et al.
patent: 6077840 (2000-06-01), Kurihara et al.
patent: 6306851 (2001-10-01), Santilli et al.
patent: 6319912 (2001-11-01), Grubb et al.
patent: 6329416 (2001-12-01), Grubb et al.
patent: 6339098 (2002-01-01), Collins et al.
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358947 (2002-03-01), Zhi et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6369056 (2002-04-01), Zhang et al.
patent: 6380178 (2002-04-01), Grubb et al.
patent: 6380235 (2002-04-01), Zhang et al.
patent: 6391907 (2002-05-01), Fensome et al.
patent: 6399593 (2002-06-01), Grubb et al.
patent: 6436929 (2002-08-01), Zhang et al.
patent: 6566372 (2003-05-01), West et al.
patent: 2003/0130505 (2003-07-01), Zhi et al.
patent: 3633861 (1988-04-01), None
patent: 4330234 (1995-03-01), None
patent: 4344463 (1995-06-01), None
patent: 022317 (1981-01-01), None
patent: 208510 (1987-01-01), None
patent: 311135 (1989-04-01), None
patent: 0 166 533 (1990-04-01), None
patent: 385850 (1990-09-01), None
patent: 483077 (1991-09-01), None
patent: 454330 (1991-10-01), None
patent: 535529 (1992-09-01), None
patent: 510235 (1992-10-01), None
patent: 947507 (1999-10-01), None
patent: 978279 (2000-02-01), None
patent: 63112584 (1988-05-01), None
patent: WO86/03749 (1986-07-01), None
patent: WO91/04974 (1991-04-01), None
patent: WO91/06545 (1991-05-01), None
patent: WO93/12085 (1993-06-01), None
patent: WO94/14434 (1994-07-01), None
patent: WO94/29272 (1994-12-01), None
patent: WO95/11013 (1995-04-01), None
patent: WO95/20389 (1995-08-01), None
patent: WO95/20972 (1995-08-01), None
patent: WO95/33746 (1995-12-01), None
patent: WO96/15794 (1996-05-01), None
patent: WO96/19458 (1996-06-01), None
patent: WO96/19997 (1996-07-01), None
patent: WO97/13767 (1997-04-01), None
patent: WO97/49407 (1997-12-01), None
patent: WO98/14436 (1998-04-01), None
patent: WO98/27059 (1998-06-01), None
patent: WO98/55116 (1998-12-01), None
patent: WO99/10325 (1999-03-01), None
patent: WO99/11264 (1999-03-01), None
patent: WO99/15500 (1999-04-01), None
patent: WO99/44608 (1999-09-01), None
patent: WO-01/15108 (2001-03-01), None
Wolters Kluwer Co., Drug Facts and Comparisons, 1995 Edition, (c) 1995, St. Louis, MO, pp. 388, 395, 396.
R. Evans, “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, 240:889 (May 13, 1988).
A. Ulmann et al, “Clinical Uses of Mifepristone (MFP)”, Ann. N.Y. Acad. Sci. 261:248 (Jun. 12, 1995).
R. Kekkonen et al, “Sequential Regiment of the Antiprogesterone RU486 and Synthetic Progestin for Contraception”, Fertility and Sterility, 60(4):610 (Oct., 1993).
K. Horwitz et al, “Progestin, Progesterone Receptors, and Breast Cancer”, Horm. Cancer, publisher: Birkhaeuser, Boston, Mass., ed. Vedeckis, pp. 283-306 (1996).
A. Murphy et al, “Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU486”, J. Clin. Endo. Metab., 76(2):513 (Feb., 1993).
L. Kettel et al, “Endocrine Responses to Long-Term Administration of the Antiprogesterone RU486 in Patients with Pelvic Endometriosis”, Fertility and Sterility, 56(3):402 (Sep., 1991).
H. Michna et al, “Differentiation Therapy with Progesterone Antagonists”, Ann. N.Y. Acad. Sci., 761:224 (Jun., 1995).
L. Zhi et al, “5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists”, J. Med. Chem., 41(3):291 (Oct. 22, 1998).
D. Combs et al, “Nonsteroidal Progesterone Receptor Ligands 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone Receptors”, J. Med. Chem., 38:4880 (Dec. 8, 1995).
K. Perlman et al, “20-Oxopregnacalciferosl: Vitamin D Compounds that Bind the Progesterone Receptor”, Tet. Letters, 35(15)2295 (1994).
L. Hamann et al, “Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists”, Ann. N.Y. Acad. Sci., 761:383 (Jun. 12, 1995).
R. Chen et al, “Synthesis and SAR of a Novel Series of Spirobenzothlzaepine Derivatives with Antiprogestin Activity”, POI-37, 16thInt. Cong. Het. Chem., Montana (1997).
B. Narr et al, “Preparation, Testing, and Formulation of Imidazobenzoxazinones as Cardiotonics”, Chemical Abstracts, 109:22973 (1988).
R. Hartmann et al, “Effects of Brofoxine, A New Anxiolytic on Experimentally Induced Conflict in Rats”, Proc. West. Pharmacol. Soc., 21:51-55 (1978).
B. Singh et al, “Novel cAMP PDE III Inhibitor” Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3H)-ones and their Analogs, J. Med. Chem., 37:248 (Jan. 21, 1994).
A. Andreani et al, “Potential Antitumor Agents XVII (1). Cytotoxic Agents from Indole Derivatives and their Intermediates”, Acta. Pharm. Nord., 2(6):407 (1990).
Sakata et al, “Silver Halide Photographic Materials Useful for Platemaking”, Chemical Abstracts, 123:301431 (1993).
P. Pflegel et al, “Polarografie con 7-Chlor-5-phenyl-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepinen”, Pharmazie, 37(10):714-717 (1982).
E. Barengolts et al, “Progesterone Antagonist RU486 has Bone-Sparing Effects in Ovariectomized Rats”, Bone, 17(1):21 (Jul., 1995).
E. Gromachevskaya et al, “Studies of 4H-3, 1-Benzoxazines”, Chem. Heterocycl. Cmpds., 33(10):1209-1214 (1997).
D. Chiarino et al, “2, 1-Benzisothiazoline 2,2-Dioxide and Derivatives”, J. Heterocycl. Chem, 23(6):1645-1649 (Nov.-Dec., 1986).
A. Turck et al, “On the Metabolism of 3-Substituted and 3,6-Disubstituted Pyridazines”, Tetrahedron, 49(3):599-606 (1993).
V. Kumar et al, “Synthesis of.7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross-Coupling Reaction”, J. Org. Chem., 57(25):6995-6998 (1992)
Collins Mark A.
Edwards James P.
Fensome Andrew
Jones Todd K.
Tegley Christopher M.
Howson and Howson
Ligand Pharmaceuticals Inc.
Truong Tamthom N.
Wilson James O.
Wyeth
LandOfFree
Cyclothiocarbamate derivatives as progesterone receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclothiocarbamate derivatives as progesterone receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclothiocarbamate derivatives as progesterone receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587452